Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sophiris Bio

Nasdaq:SPHS
Snowflake Description

Imperfect balance sheet with poor track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SPHS
Nasdaq
€6M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Sophiris Bio has significant price volatility in the past 3 months.
SPHS Share Price and Events
7 Day Returns
-3.5%
NasdaqGM:SPHS
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-80.6%
NasdaqGM:SPHS
1.6%
US Biotechs
-9.1%
US Market
SPHS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sophiris Bio (SPHS) -3.5% -70.2% -43.2% -80.6% -93.2% -72.1%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • SPHS underperformed the Biotechs industry which returned 1.6% over the past year.
  • SPHS underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
SPHS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Sophiris Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sophiris Bio. This is due to cash flow or dividend data being unavailable. The share price is $0.1925.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sophiris Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sophiris Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SPHS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $0.00
DB:BFF1 Share Price ** DB (2020-03-27) in EUR €0.18
DB:BFF1 Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.109 $0.2
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sophiris Bio.

NasdaqGM:SPHS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:BFF1 Share Price ÷ EPS (both in USD)

= 0.2 ÷ 0.00

165.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sophiris Bio is overvalued based on earnings compared to the US Biotechs industry average.
  • Sophiris Bio is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Sophiris Bio's expected growth come at a high price?
Raw Data
NasdaqGM:SPHS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 165.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-65.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

NasdaqGM:SPHS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 165.49x ÷ -65.7%

-2.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sophiris Bio earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sophiris Bio's assets?
Raw Data
NasdaqGM:SPHS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.08
DB:BFF1 Share Price * DB (2020-03-27) in EUR €0.18
DB:BFF1 Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.109 $0.2
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:SPHS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:BFF1 Share Price ÷ Book Value per Share (both in USD)

= 0.2 ÷ -0.08

-2.43x

* Primary Listing of Sophiris Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sophiris Bio has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
X
Value checks
We assess Sophiris Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sophiris Bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sophiris Bio expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-65.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sophiris Bio expected to grow at an attractive rate?
  • Sophiris Bio's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Sophiris Bio's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Unable to compare Sophiris Bio's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SPHS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SPHS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -65.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SPHS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SPHS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -16 1
2020-12-31 0 -13 2
2019-12-31 0 -8 2
NasdaqGM:SPHS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -11 0
2019-06-30 -12 -2
2019-03-31 -13 -6
2018-12-31 -13 -7
2018-09-30 -14 -16
2018-06-30 -12 -16
2018-03-31 -11 -9
2017-12-31 -10 -9
2017-09-30 -9 -5
2017-06-30 -10 -7
2017-03-31 -11 -12
2016-12-31 -10 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sophiris Bio's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Sophiris Bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SPHS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Sophiris Bio Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SPHS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
NasdaqGM:SPHS Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 0.00
2019-06-30 -0.06
2019-03-31 -0.19
2018-12-31 -0.23
2018-09-30 -0.54
2018-06-30 -0.53
2018-03-31 -0.31
2017-12-31 -0.29
2017-09-30 -0.17
2017-06-30 -0.24
2017-03-31 -0.44
2016-12-31 -0.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sophiris Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sophiris Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sophiris Bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sophiris Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sophiris Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sophiris Bio has delivered over 20% year on year earnings growth in the past 5 years.
  • Sophiris Bio has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Sophiris Bio has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
Sophiris Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sophiris Bio Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SPHS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.04 4.83 5.34
2019-06-30 -1.88 4.58 6.41
2019-03-31 -5.81 4.45 8.92
2018-12-31 -6.78 4.43 10.71
2018-09-30 -16.26 4.80 10.66
2018-06-30 -16.04 5.34 10.51
2018-03-31 -9.34 5.61 8.31
2017-12-31 -8.63 5.73 6.19
2017-09-30 -5.21 5.63 5.25
2017-06-30 -6.84 6.98 4.23
2017-03-31 -11.54 6.97 3.82
2016-12-31 -11.16 6.77 3.54
2016-09-30 -13.12 6.22 4.20
2016-06-30 -12.49 4.10 6.13
2016-03-31 -12.14 3.74 7.71
2015-12-31 -14.20 3.63 9.86
2015-09-30 -16.98 3.98 12.27
2015-06-30 -21.55 4.43 16.43
2015-03-31 -26.56 4.93 20.96
2014-12-31 -30.71 5.33 24.71
2014-09-30 0.00 -30.87 5.82 24.77
2014-06-30 0.00 -25.60 5.33 20.17
2014-03-31 0.00 -19.49 4.72 14.24
2013-12-31 5.00 -11.15 4.51 10.28
2013-09-30 5.00 -11.04 4.35 9.47
2013-06-30 5.00 -13.72 5.45 10.59
2013-03-31 5.00 -16.78 5.93 13.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sophiris Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • Sophiris Bio used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Sophiris Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sophiris Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sophiris Bio has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sophiris Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sophiris Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sophiris Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sophiris Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sophiris Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sophiris Bio has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sophiris Bio Company Filings, last reported 5 months ago.

NasdaqGM:SPHS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -2.76 5.75 6.30
2019-06-30 -2.38 6.41 6.02
2019-03-31 -0.40 7.06 9.02
2018-12-31 1.74 7.01 12.54
2018-09-30 -3.97 6.96 14.55
2018-06-30 -1.36 6.91 18.53
2018-03-31 4.55 6.86 22.05
2017-12-31 7.65 6.81 25.84
2017-09-30 11.23 6.76 28.51
2017-06-30 13.23 0.00 24.03
2017-03-31 12.13 0.00 25.69
2016-12-31 14.32 0.00 29.00
2016-09-30 14.57 0.00 31.26
2016-06-30 0.74 4.48 8.34
2016-03-31 -0.20 4.92 5.40
2015-12-31 1.91 5.34 8.38
2015-09-30 3.61 5.75 9.86
2015-06-30 7.07 6.01 13.22
2015-03-31 10.60 5.98 17.04
2014-12-31 14.69 5.94 22.70
2014-09-30 19.50 5.91 29.14
2014-06-30 27.19 5.88 35.63
2014-03-31 33.29 5.28 40.28
2013-12-31 40.28 6.88 48.15
2013-09-30 45.48 8.42 54.74
2013-06-30 -7.04 9.35 3.57
2013-03-31 -4.88 10.61 4.61
  • Sophiris Bio has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Sophiris Bio's debt level has increased considering it has negative shareholder equity.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Sophiris Bio's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Sophiris Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sophiris Bio has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sophiris Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sophiris Bio dividends.
If you bought $2,000 of Sophiris Bio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sophiris Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sophiris Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SPHS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SPHS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sophiris Bio has not reported any payouts.
  • Unable to verify if Sophiris Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sophiris Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sophiris Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sophiris Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sophiris Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sophiris Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sophiris Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Randy Woods
COMPENSATION $774,526
AGE 67
TENURE AS CEO 7.6 years
CEO Bio

Mr. Randall E. Woods, also known as Randy, has been the Chief Executive Officer and President of Sophiris Bio, Inc. since August 16, 2012. Mr. Woods founded and served as the President and Chief Executive Officer of Sequel Pharmaceuticals, Inc. He served as President and Chief Executive Officer of Novacardia, Inc. since May 2004. He served as President and Chief Executive Officer of Corvas International Inc. until 2003. Prior to joining Corvas, Mr. Woods served as the President of the U.S. Operations, Boehringer Mannheim Pharmaceuticals Corporation, or Boehringer, from February 1994 to March 1996 and served as Vice President of Marketing and Sales from December 1993 to March 1994. He has been the Chairman of the Board at Sorbent Therapeutics, Inc., since April 2012. He founded and serves as Chairman of the Board at Selexagen Therapeutics, Inc. He is a past Chairman for the Advisory Board of UC San Diego's Sulpizio Family Cardiovascular Center and is a past Chairman of the Board of Directors for BIOCOM, a life science industry association in Southern California. He serves as a Director of Biocom SA. He has been a Director at Sophiris Bio, Inc. since October 4, 2012. He has been a Director of Novacardia, Inc. since May 2004. He has been an Independent Director at Arena Pharmaceuticals, Inc. since December 2007. He serves as Member of the Business Advisory Board of Ultreia Capital. He serves as a Director of Oasis Biosciences, Inc. He serves as Member of the Business Advisory Board at affentranger associates sa, Investment arm. He served as the Director of Sequel Pharmaceuticals, Inc. He served in various capacities at Eli Lilly and Company from 1973 to December 1993. He served as a Director of Corvas International, Inc. since May 1996. He holds an M.B.A. from Western Michigan University in Marketing and BSc in Biology and Chemistry from Ball State University.

CEO Compensation
  • Randy's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Randy's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sophiris Bio management team in years:

10
Average Tenure
47
Average Age
  • The average tenure for the Sophiris Bio management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Randy Woods

TITLE
President
COMPENSATION
$775K
AGE
67
TENURE
7.6 yrs

Peter Slover

TITLE
Chief Financial Officer
COMPENSATION
$504K
AGE
44
TENURE
7.2 yrs

Sam Denmeade

TITLE
Chief Scientific Officer & Member of the Scientific Advisory Board
TENURE
12.4 yrs

James Beesley

TITLE
Senior Director of Investor Relations
AGE
47

Iain Mant

TITLE
Corporate Secretary
TENURE
12.9 yrs
Board of Directors Tenure

Average tenure and age of the Sophiris Bio board of directors in years:

3.4
Average Tenure
67
Average Age
  • The tenure for the Sophiris Bio board of directors is about average.
Board of Directors

Lars Ekman

TITLE
Independent Chairman of the Board
COMPENSATION
$143K
AGE
69
TENURE
8.9 yrs

Randy Woods

TITLE
President
COMPENSATION
$775K
AGE
67
TENURE
7.4 yrs

Sam Denmeade

TITLE
Chief Scientific Officer & Member of the Scientific Advisory Board

Jack Geltosky

TITLE
Independent Director
COMPENSATION
$111K
AGE
73
TENURE
11.5 yrs

Gerry Proehl

TITLE
Independent Director
COMPENSATION
$119K
AGE
60
TENURE
6 yrs

Allison Hulme

TITLE
Director
COMPENSATION
$703K
AGE
56
TENURE
3.4 yrs

Hashim Ahmed

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs

Scott Coffield

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs

Scott Eggener

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs

Mark Emberton

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Sophiris Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sophiris Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company’s primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Details
Name: Sophiris Bio, Inc.
SPHS
Exchange: NasdaqGM
Founded: 2002
€6,879,904
34,472,140
Website: http://www.sophirisbio.com
Address: Sophiris Bio, Inc.
1258 Prospect Street,
La Jolla,
California, 92037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB BFF1 Common Shares Deutsche Boerse AG DE EUR 13. Aug 2003
NasdaqGM SPHS Common Shares Nasdaq Global Market US USD 13. Aug 2003
Number of employees
Current staff
Staff numbers
6
Sophiris Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:05
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2019/12/24
Last earnings filing: 2019/11/08
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.